Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2019
Price : $35 *
At a glance
- Drugs Axitinib (Primary)
- Indications Paraganglioma
- Focus Therapeutic Use
- 06 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 31 Aug 2018 Biomarkers information updated
- 05 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.